ArticleEuropean urology2020
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5.
Abstract readEditorialComment
In one paragraph
Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
- Comment on
Authors and funding
42 authors.
Aurélie KamounCartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France. Electronic address: aurelie.kamoun@ponts.org.
Aurélien de ReynièsCartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France.
Yves AlloryDepartment of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Gottfrid SjödahlDivision of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
A Gordon RobertsonCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC, Canada.
Roland SeilerDepartment of Urology, Bern University Hospital, Bern, Switzerland.
Katherine A HoadleyDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Clarice S GroeneveldCartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil.
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Woonyoung ChoiJohns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Mauro A A CastroBioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil.
Jacqueline FontugneDepartment of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Pontus ErikssonDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Qianxing MoDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jordan KardosDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alexandre ZlottaDivision of Urology, Department of Surgery, University of Toronto, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada.
Arndt HartmannInstitute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
Colin P DinneyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joaquim BellmuntBladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Thomas PowlesBarts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK.
Núria MalatsGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
Keith S ChanCedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA.
William Y KimDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David J McConkeyJohns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Lars DyrskjøtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Mattias HöglundDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Seth P LernerScott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Francisco X RealEpithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
François RadvanyiInstitut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Mattias AineDivision of Molecular Hematology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden.
Isabelle Bernard-PierrotInstitut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Bogdan CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ewan A GibbGenomeDx Biosciences Inc., Vancouver, BC, Canada.
Jaegil KimBroad Institute of MIT and Harvard, Cambridge, MA, USA.
David J KwiatkowskiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Thierry LebretDepartment of Urology, University of Versailles-Saint-Quentin-en-Yvelines, Foch Hospital, Suresnes, France.
Fredrik LiedbergDivision of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
A Arlene Siefker-RadtkeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nanor SirabDepartment of Pathology, Institut Curie Hospital Group, Paris, France.
Ann TaberDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
John N WeinsteinDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Urinary Bladder NeoplasmsConsensusGenomicsHumans
Identifiers
PMID
32037144What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.